Who is sponsoring NCT04063813?

NCT04063813 is sponsored by University of Michigan.

What drugs are being tested in NCT04063813?

Interventions in NCT04063813: Experimental: 40 minute up trial, Experimental: 40 minute down trial, Experimental: Two 20 minute up trials, Experimental: Two 20 min down trials, Active Comparator: Sedentary trial.

What condition does NCT04063813 study?

NCT04063813 studies Osteoporosis, Postmenopausal.

Is NCT04063813 still recruiting?

NCT04063813 is currently completed. Last updated 21 August 2019.

Last reviewed 2019-08-21 · How we verify

NCT04063813: OSTEOPOROSISEX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Parameters of Exercise to Prevent Osteoporosis

Completed NA Last updated 21 August 2019

What this trial tests

NA trial testing Experimental: 40 minute up trial in Osteoporosis, Postmenopausal in 40 participants. Completed in 19 August 2010.

Timeline

15 May 2007

Primary endpoint
19 August 2010

19 August 2010

Quick facts

Lead sponsor	University of Michigan
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	40
Start date	15 May 2007
Primary completion	19 August 2010
Estimated completion	19 August 2010
Sites	1 location across United States

Drugs / interventions tested

Experimental: 40 minute up trial
Experimental: 40 minute down trial
Experimental: Two 20 minute up trials
Experimental: Two 20 min down trials
Active Comparator: Sedentary trial

Conditions studied

Osteoporosis, Postmenopausal — all drugs for Osteoporosis, Postmenopausal →

Sponsor

University of Michigan

Who can join

Adults 50 to 65, female only, with Osteoporosis, Postmenopausal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The principal goal of this study is to determine parameters of walking in terms of peak mechanical vertical force, bout duration, and bout spacing that can preserve or increase bone mineral density (BMD) in postmenopausal women. Release of pulses of parathyroid hormone (PTH), growth hormone (GH), and of markers of bone resorption and bone formation will be used as indicators of the osteogenic effects of a short exposure to exercise. When secreted in pulsatile fashion, GH stimulates osteoblast proliferation, particularly in cortical bone (27, 28). Like GH, the pattern of PTH secretion determines the nature of its effect on bone. When it is secreted in pulsatile manner, PTH contributes to bone formation through activation of bone lining cells, differentiation of osteoprogenitor cells, and suppression of bone cell apoptosis .

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Anabolic Bone Stimulus Requires a Pre-Exercise Meal and 45-Minute Walking Impulse of Suprathreshold Speed-Enhanced Momentum to Prevent or Mitigate Postmenopausal Osteoporosis within Circadian Constraints.
Zheng Q, Kernozek T, Daoud-Gray A, Borer KT. · · 2021 · cited 10× · PMID 34835982 · DOI 10.3390/nu13113727

Verify or expand the search:

Other recruiting trials for Osteoporosis, Postmenopausal

Currently open trials in the same condition.

NCT07242612 — Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis · NA · recruiting
NCT06558188 — Combined Anabolic Therapy · Phase 4 · recruiting
NCT06655701 — Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis · recruiting
NCT06525688 — New Biomarkers and Therapeutic Targets in Osteoporosis Via Omics Technologies · recruiting
NCT05655013 — Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2) · Phase 4 · active not recruiting

Other University of Michigan trials

Trials by the same sponsor.

NCT07536919 — Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation · NA · not yet recruiting
NCT05509842 — Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD) · NA · not yet recruiting
NCT06311188 — Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness · NA · not yet recruiting
NCT07471646 — Effects of Ramadan Fasting With Exercise on Cardiometabolic Health · NA · not yet recruiting
NCT06671925 — A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04063813 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan
Last refreshed: 21 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04063813.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing